Plexus Corp. walks into its fiscal Q3 print today having shed 16% over the past month — and the CEO has been selling the whole way down.
The insider angle is the sharpest context heading into the release. CEO Todd Kelsey sold shares on at least five separate occasions since late May, offloading stock at prices between $261 and $296 — well above where the stock now trades at $240. Total net selling across all insiders over the past 90 days exceeded 26,000 shares, worth roughly $7 million. These were relatively small positions as a percentage of the company, and significance scores were modest, but the pattern of a CEO consistently selling into a rising stock — which then corrected — frames the print with an awkward backdrop.
The analyst community remains constructive on paper, but the consensus is now stale. Stifel raised its target to $330 and upgraded the stock to Buy in late June; Needham lifted to $310 in early June. Both moves came when the stock was still trading above $270. The consensus mean target of $293 now sits well above the current price, implying theoretical upside of around 22% — but those targets predate a 16% decline, and no analyst has updated since the selloff accelerated. Bulls lean on Plexus's exposure to aerospace, defense, and medical devices as a durable earnings engine. Bears point to slowing demand in healthcare and life sciences, potential normalization of semiconductor capital equipment spending, and the risk that margins disappoint if end-market momentum has softened.
Options positioning has become more cautious since yesterday's preview, though it has not escalated further. The put/call ratio ticked to 0.257, still running above its 20-day average of 0.175 and roughly 1.2 standard deviations above the norm — elevated, but not at extremes. The 52-week high PCR of 0.61 shows there is headroom for hedging to intensify if the print disappoints. Short interest remains a non-event at 3.1% of the float, with borrow availability near 6,600% — roughly 10 million shares available to lend with cost to borrow at a negligible 0.42%. The lending market is entirely relaxed. Notably, peers sold off harder on the day: TTMI fell 12% and BELF.A dropped 7%, with BHE down 9% on the week — suggesting sector-wide pressure that PLXS has so far absorbed less severely than its closest correlates.
The print will test whether Plexus's premium positioning in higher-value end markets — aerospace, defense, medical — can justify a valuation that still prices in meaningful growth, even after the stock's sharpest monthly decline of the year.
See the live data behind this article on ORTEX.
Open PLXS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
